Horizon Therapeutics (HZNP) is a company that got on my radar earlier this year when their thyroid eye disease treatment, TEPEZZA, received FDA approval 2 months ahead of schedule. The more I’ve researched this biopharma company, the more I like what I see. Horizon’s sales have been growing strongly for years now, and there’s no slow-down in sight.
Horizon has transformed itself into a rare-disease specialist that might well have 2 blockbuster drugs on its hands in a few years. Management has diligently reinvested cash-flow into acquisitions and pipeline development, generating compounded returns